SOPHiA GENETICS (SOPH) Q4 2025 Earnings Transcript

Motley Fool Transcribing, The Motley Fool

Tue, March 3, 2026 astatine 8:26 AM CST 39 min read

Image source: The Motley Fool.

March 3, 2026, 8 a.m. ET

• Chief Executive Officer — Jurgi Camblong

• Chief Financial Officer — George A. Cardoza

• Chief Operating Officer — Ross Muken

• Head of Investor Relations — Kellen Sanger

Jurgi Camblong: Thanks, Kellen, and bully morning, everyone. I volition commencement with a little recap of Q3 show and an update connected large maturation drivers. I volition past crook the telephone implicit to Ross, who volition supply a much elaborate update connected the business. George volition adjacent with a reappraisal of our Q3 fiscal show earlier we instrumentality your questions. For the past respective quarters, we person highlighted that the concern momentum has been strong. New lawsuit signings person been astatine grounds levels and bookings person exceeded expectations. In Q3, these efforts continued to wage disconnected arsenic gross maturation accelerated for a 3rd consecutive quarter. Revenue grew 23% twelvemonth implicit twelvemonth successful Q3.

Given the beardown show and the accelerating momentum we are seeing crossed the business, we are raising our 2025 gross guidance to $75 cardinal to $77 million. Our show continues to beryllium driven by the 3 maturation drivers we outlined astatine the commencement of the year: implementing and expanding crossed caller accounts, increasing successful the U.S. market, and capitalizing connected caller applications specified arsenic MSK Access. Starting with the archetypal maturation driver, successful Q3, we signed 31 caller customers. This brings our full caller customers signed successful 2025 to 94, surpassing the 92 customers we signed successful each of past year. Our absorption remains connected implementing and expanding crossed these caller accounts.

From an grow perspective, we had an fantabulous 4th arsenic we successfully encouraged galore of our existing customers to follow further applications. In Q3, we expanded our footprint astatine respective top-ranked institutions. Gustave Roussy successful Paris is adding caller coagulated tumor applications to the wide suite of SOPHiA apps they usage today. Institute nationalist successful Marseille signed a large grow woody to adhd HemOnc, hereditary cancer, and coagulated tumor applications. In addition, New South Wales Pathology, Australia, is adding a implant exertion and Tulane University successful the U.S. is adding caller applications successful coagulated tumors. Congratulations to the squad connected these large expands, arsenic good arsenic the 31 caller customers landed successful the quarter.

I look guardant to these customers implementing SOPHiA DDM and opening to make gross implicit the adjacent fewer months. On implementations, we were blessed to spot 15 sizable caller customers determination to regular successful Q3. We besides implemented an abnormally ample fig of grow opportunities during the quarter. Between some onshore and expand, full caller concern implemented successful Q3 was strong. The 2nd maturation operator I volition item is our continued maturation successful the U.S. market. In Q3, U.S. gross grew an awesome 30% twelvemonth implicit twelvemonth connected apical of an progressively larger base. We besides signed a beardown cohort of caller customers to substance growth.